Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 71Lymphoma, Large B-Cell, Diffuse 51Neoplasms 41Lymphoma, Non-Hodgkin 41Multiple Myeloma 40Lymphoma 37Recurrence 35Lymphoma, Follicular 30Carcinoma, Non-Small-Cell Lung 30Leukemia, Lymphocytic, Chronic, B-Cell 29Lymphoma, B-Cell 26Triple Negative Breast Neoplasms 23Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Pancreatic Neoplasms 15Neoplasm Metastasis 15Leukemia 15Squamous Cell Carcinoma of Head and Neck 12Melanoma 12Stomach Neoplasms 11Colorectal Neoplasms 11Lymphoma, B-Cell, Marginal Zone 10Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, T-Cell, Peripheral 8Liposarcoma, Myxoid 8Carcinoma, Renal Cell 8Sarcoma 7

Interventions

pegfilgrastim 7NPI 2358 4Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Docetaxel 3balugrastim 2Drug Therapy 2Cyclophosphamide 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Chemotherapy-induced Neutropenia × Cyclophosphamide × Clear all
NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡